The Evolution of Medicine

Levana Biologics has partnered with a world-renowned University to offer the healthcare community high-quality biomaterials that are manufactured and delivered with integrity.

For over a century, human birth tissue and its’ derivatives have been used for tissue remodeling and regeneration. Recent and rapid developments in bioengineering techniques have reintroduced this “native” biomaterial to modern-day medicine, providing a safe and natural approach to treat patients suffering from a variety of medical conditions. The unlimited potential and the diverse applications of these tissues is redefining healthcare outcomes worldwide, delivering promising results and more practical solutions for both patients and providers. Levana Biologics provides healthcare professionals “smart” metabolically active biomaterials that supercharge the body’s own stem cells to enhance, promote, and stimulate the natural healing process.

Wound Healing    Oral & Periodontal Applications    Orthopedics & Pain Management    Ophthalmology    Urology    Sports Injuries    Musculoskeletal & Spine    Cosmetic Indications    Systemic Issues

For more uses and applications see in dropdown below

Uses Disclaimer: Levana Biologics manufacturer has supplied 1,000+ units of LevaSOLTM and 4,000+ units of LevaGRAFTM for various applications. This list is not inclusive of all potential applications. Not all uses and applications listed have successfully completed IRB approvals. Some of these applications are currently undergoing clinical trials. It is up to the clinician to determine its’ usefulness or effectiveness.

Products

Photo: LevaSOLTM amniotic fluid allografts offered in both a vial and eye dropper format

LevaSOLTM

is a decellularized human amniotic fluid allograft that has been bioengineered utilizing a cutting-edge sterile filtration technology that delicately extracts dead tissue and debris from the fluid. LevaSOLTM has been cryopreserved to ensure maximum patient safety while preserving high concentrations of the beneficial proteins, extracellular matrix components and hyaluronic acid. Components of LevaSOLTM interact with Multiple Tissue Types to enhance the body’s own healing process and stimulate normal regeneration to provide strength in healing.Data on file

Dehydrated/Crosslinked LevaGRAF Allograft 1 x 1 -cm

Photo: 1 x 1-cm2  Dehydrated LevaGRAFTM

LevaGRAFTM

is a terminally-sterilized, cryoprotectant and chorion-free human amniotic membrane allograft, that has been cross-linked and bioengineered utilizing a proprietary mechanism to both prolong and sustain the beneficial nutrients and growth factors following transplantation. LevaGRAFTM is offered in hydrated and dehydrated formats that can be stored at room temperature to provide the clinician with more durability and handling flexibility. Data on file

Human Amniotic Membrane and Fluid Allografts in Regenerative Medicine

“Regenerative medicine, a commonly used phrase in the field of chronic wound management, is the “process of replacing or regenerating human cells, tissues, or organs to restore or establish normal function” (1). The term also refers to a group of biomedical approaches to clinical therapies that involve the use of stem cells. Tissue-engineered skin and platelet-derived growth factors represent substantial advancements in wound healing, because they stimulate the delivery of certain factors considered important to regenerative medicine, including growth factors, fibroblasts, collagen, and a physical scaffold on which wound repair and regeneration can occur. The amniotic membrane (AM) or amnion is a tissue of particular interest because it can provide cells with multipotency. Amnion is easily obtained after cesarean delivery, because the placenta and associated fluid and membrane are typically discarded after childbirth. The cells have been shown to have extremely low immunogenicity, and their procurement avoids the controversies associated with obtaining human embryonic stem cells. Thus, the use of AM and amniotic fluid (AF) has been proposed as a potentially useful allograft cell therapy in regenerative medicine.” (2).